EA202190576A1 - Полиморфные соединения и их применение - Google Patents
Полиморфные соединения и их применениеInfo
- Publication number
- EA202190576A1 EA202190576A1 EA202190576A EA202190576A EA202190576A1 EA 202190576 A1 EA202190576 A1 EA 202190576A1 EA 202190576 A EA202190576 A EA 202190576A EA 202190576 A EA202190576 A EA 202190576A EA 202190576 A1 EA202190576 A1 EA 202190576A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- application
- polymorphic compounds
- compounds
- polymorphic
- stroke
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 230000006931 brain damage Effects 0.000 abstract 1
- 231100000874 brain damage Toxicity 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736979P | 2018-09-26 | 2018-09-26 | |
| PCT/US2019/053076 WO2020069068A1 (en) | 2018-09-26 | 2019-09-26 | Polymorphic compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190576A1 true EA202190576A1 (ru) | 2021-09-03 |
Family
ID=69885558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190576A EA202190576A1 (ru) | 2018-09-26 | 2019-09-26 | Полиморфные соединения и их применение |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10765693B2 (https=) |
| EP (1) | EP3856741A4 (https=) |
| JP (2) | JP2022502405A (https=) |
| KR (1) | KR20210093864A (https=) |
| CN (1) | CN112930349A (https=) |
| AU (1) | AU2019346585B2 (https=) |
| BR (1) | BR112021005290A2 (https=) |
| CA (1) | CA3113250A1 (https=) |
| EA (1) | EA202190576A1 (https=) |
| IL (1) | IL281718A (https=) |
| MX (1) | MX2021003515A (https=) |
| WO (1) | WO2020069068A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102445887B1 (ko) | 2016-04-21 | 2022-09-21 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 |
| IL276358B2 (en) | 2018-02-09 | 2024-11-01 | Astrocyte Pharmaceuticals Inc | Compounds and methods for treating addiction and related disorders |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| MX2023014655A (es) | 2021-07-12 | 2024-01-12 | Acadia Pharm Inc | Formas cristalinas de trofinetida. |
| WO2023091791A1 (en) * | 2021-11-22 | 2023-05-25 | Astrocyte Pharmaceuticals, Inc. | Methods of treating neurological and cardiovascular conditions |
| WO2024097387A1 (en) * | 2022-11-03 | 2024-05-10 | Astrocyte Pharmaceuticals, Inc. | Compositions for intravenous administration |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69428536T2 (de) | 1993-07-13 | 2002-06-06 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A3 -adenosin -rezeptor agonisten |
| US7348315B2 (en) | 1995-03-23 | 2008-03-25 | The University Of Connecticut | Methods of treating heart failure with modified ATP, ADP and AMP compounds |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| US6586413B2 (en) | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US7087589B2 (en) * | 2000-01-14 | 2006-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methanocarba cycloakyl nucleoside analogues |
| JP4012070B2 (ja) | 2001-01-16 | 2007-11-21 | カン−フィテ・バイオファーマ・リミテッド | ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用 |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| US7557092B2 (en) | 2002-11-21 | 2009-07-07 | University Of Utah Research Foundation | Purinergic modulation of smell |
| GB0405009D0 (en) * | 2004-03-05 | 2004-04-07 | Cambridge Biotechnology Ltd | Analgesics |
| JP2008512457A (ja) | 2004-09-09 | 2008-04-24 | アメリカ合衆国 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| WO2007020018A1 (en) | 2005-08-12 | 2007-02-22 | Universite Libre De Bruxelles | Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
| WO2007139775A2 (en) | 2006-05-23 | 2007-12-06 | University Of Connecticut | N-methanocarba derivatives to treat cardiac diseases |
| WO2008021552A2 (en) | 2006-08-18 | 2008-02-21 | Duke University | Biased ligands and methods of identifying same |
| US7867983B2 (en) | 2007-03-29 | 2011-01-11 | The University Of Connecticut | Methods to protect skeletal muscle against injury |
| JP5592262B2 (ja) | 2007-10-15 | 2014-09-17 | キャン−ファイト・バイオファーマ・リミテッド | 肝細胞の増殖を誘導する方法及びその使用 |
| US20100256086A1 (en) | 2007-11-23 | 2010-10-07 | Bar-Ilan Univetrsity | Non-hydrolyzable nucleoside di- or tri-phosphate derivatives and uses thereof |
| CA2720037C (en) | 2008-03-31 | 2016-08-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as a3 adenosine receptor-selective agonists |
| WO2010014921A2 (en) | 2008-08-01 | 2010-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| KR20130097813A (ko) | 2008-04-21 | 2013-09-03 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| EP2429565A4 (en) | 2009-04-15 | 2012-11-14 | Univ California | NEURONIC OR NERVE PEPTIDES AND APTAMERS |
| WO2011068978A1 (en) | 2009-12-02 | 2011-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methanocarba adenosine derivatives and dendrimer conjugates thereof |
| WO2011077435A1 (en) | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
| ES2654363T3 (es) | 2010-02-22 | 2018-02-13 | University Of Connecticut | Derivados de AMP para tratar enfermedades cardíacas |
| US8691775B2 (en) | 2010-04-19 | 2014-04-08 | Back Bay Scientific, Llc | Use of drugs that activate P2Y receptors to enhance synaptogenesis |
| US9132131B2 (en) | 2011-04-21 | 2015-09-15 | Saint Louis University | Use of adenosine A3 receptor agonists for treatment of neuropathic pain |
| US20140241990A1 (en) | 2011-09-30 | 2014-08-28 | Tufts University | Methods of using adenosine a1 receptor activation for treating depression |
| EA034135B9 (ru) | 2013-03-13 | 2020-04-10 | Тафтс Юниверсити | Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов |
| WO2015080940A1 (en) | 2013-11-27 | 2015-06-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| EP3253388A4 (en) | 2015-02-04 | 2018-11-21 | Baker Heart and Diabetes Institute | A method of treatment and compounds for use therein |
| KR102445887B1 (ko) | 2016-04-21 | 2022-09-21 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 |
| IL276358B2 (en) * | 2018-02-09 | 2024-11-01 | Astrocyte Pharmaceuticals Inc | Compounds and methods for treating addiction and related disorders |
-
2019
- 2019-09-26 EA EA202190576A patent/EA202190576A1/ru unknown
- 2019-09-26 US US16/583,570 patent/US10765693B2/en active Active
- 2019-09-26 EP EP19867559.7A patent/EP3856741A4/en active Pending
- 2019-09-26 MX MX2021003515A patent/MX2021003515A/es unknown
- 2019-09-26 CA CA3113250A patent/CA3113250A1/en active Pending
- 2019-09-26 AU AU2019346585A patent/AU2019346585B2/en active Active
- 2019-09-26 CN CN201980071019.6A patent/CN112930349A/zh active Pending
- 2019-09-26 BR BR112021005290-9A patent/BR112021005290A2/pt unknown
- 2019-09-26 WO PCT/US2019/053076 patent/WO2020069068A1/en not_active Ceased
- 2019-09-26 KR KR1020217012486A patent/KR20210093864A/ko not_active Ceased
- 2019-09-26 JP JP2021516916A patent/JP2022502405A/ja active Pending
-
2020
- 2020-07-28 US US16/940,451 patent/US11324769B2/en active Active
-
2021
- 2021-03-22 IL IL281718A patent/IL281718A/en unknown
-
2024
- 2024-06-27 JP JP2024104074A patent/JP2024114885A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL281718A (en) | 2021-05-31 |
| KR20210093864A (ko) | 2021-07-28 |
| JP2024114885A (ja) | 2024-08-23 |
| US10765693B2 (en) | 2020-09-08 |
| WO2020069068A1 (en) | 2020-04-02 |
| AU2019346585B2 (en) | 2025-02-27 |
| WO2020069068A9 (en) | 2020-05-14 |
| EP3856741A1 (en) | 2021-08-04 |
| CN112930349A (zh) | 2021-06-08 |
| BR112021005290A2 (pt) | 2021-06-22 |
| NZ774215A (en) | 2025-03-28 |
| MX2021003515A (es) | 2021-05-27 |
| US20200093848A1 (en) | 2020-03-26 |
| US20210077518A1 (en) | 2021-03-18 |
| US11324769B2 (en) | 2022-05-10 |
| AU2019346585A1 (en) | 2021-04-29 |
| EP3856741A4 (en) | 2022-06-22 |
| CA3113250A1 (en) | 2020-04-02 |
| JP2022502405A (ja) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| MX2021010198A (es) | Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| EA201892008A1 (ru) | Соединения и способы лечения неврологических и сердечно-сосудистых состояний | |
| EA202190576A1 (ru) | Полиморфные соединения и их применение | |
| MX2023015185A (es) | Degradadores de proteinas y usos de los mismos. | |
| EP4017489C0 (en) | DGD1202 FOR THE TREATMENT OF KRAS-MUTATED CANCERS | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EA201991553A1 (ru) | (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды | |
| EP3784260A4 (en) | Compositions for the treatment of skin conditions | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| EP3802539C0 (en) | NOVEL TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| CL2018000375A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1. | |
| EP3807270C0 (en) | NOVEL HETEROCYCLYL HETEROARYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | |
| EP3790563A4 (en) | Compositions for the treatment of skin conditions | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| EP4218626C0 (en) | DEVICE FOR THE TREATMENT OF ISCHEMIA | |
| EA201991898A1 (ru) | Двойные ингибиторы magl и faah | |
| EP3897626C0 (en) | TINOSTAMUSTINE FOR THE TREATMENT OF MULTIPLE MYELOMA | |
| EA202090414A1 (ru) | Соединения и их применение | |
| EP3573620A4 (en) | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | |
| EP3709968C0 (de) | Emulsionen zur behandlung von schleimhautinfektionen | |
| EP4055033A4 (en) | Combination therapy to treat brain cancer | |
| EP4426686A4 (en) | N,N-DIMETHYLAMPHTAMIN ANALOGUES FOR THE TREATMENT OF CEREBRAL DISORDERS | |
| EA201992302A1 (ru) | Соединения, используемые в качестве ингибиторов alcat1 | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. |